Alberta College of Pharmacy adopts new practice standards with focus on ‘person-centred care’Alberta shifts focus to patient-centered care and proactive measures to help prevent prescribing errors. Recall: Health Canada pulls compounded semaglutide over unauthorized ingredient Novo Nordisk Canada has also warned that compounded semaglutide may expose patients to health risks. A reminder of what we're here for A crucial recent interaction reminded me how important it is that—no matter how busy— we take just a moment with each patient to do what we do best. Statins may increase the risk of myasthenia gravis and ocular myasthenia A Health Canada safety review concludes that there is a possible link between statin (HMG-CoA reductase inhibitor) use and the risk of myasthenia gravis. Amphetamines: Critical dose identified that increases risk of psychosis The risk of psychosis increased by 81% in individuals with ADHD taking doses of more than 30 mg of amphetamines, U.S. study showed. Could first-generation antihistamines be triggering seizures in young children? A new study from Korea may pose more questions than it answers. An overview of the potential benefits and risks of ketamine and as a therapeutic tool Ketamine is an approved anesthetic for surgeries, but it’s also known as a party drug with hallucinogenic effects. NEW PRODUCT: Epidiolex for adjunctive treatment of seizures Get the info you need on this new product, part of our drug news roundup for May. Can at-home DNA tests predict how you’ll respond to your medications? Pharmacists look at the risks and benefits of pharmacogenetic testing to explain the variability in drug response Health Canada grants conditional approval for Ondexxya to reverse FXa inhibitor anticoagulant effects Andexanet alfa will be used intravenously to rapidly reverse life-threatening or uncontrolled bleeding due to rivaroxaban or apixaban. 1 2 3 4 5 Next Last
